All products are intended for in vitro research only and not for human use
It has been shown to significantly enhance the healing of muscles, tendons, and ligaments while also providing protective effects on the gastrointestinal tract
Similarly, the substudy of the obesity phase 2 trial showed clear promise for retatrutide in the treatment of MASLD [47], and through its GCG receptor agonism, retatrutide may offer benefits beyond WL, through weight-independent metabolic effects at the liver [40]
Results so far have shown a pharmacokinetic profile supportive of once-daily dosing, with a safety profile consistent with previous danuglipron studies, including no liver enzyme elevations in over 1,400 study participants
A 6 mm needle may be adequate for lean individuals with thin subcutaneous layers, while those with greater adipose tissue may benefit from slightly longer needles to ensure reliable subcutaneous placement